Study M778
Study name | Chen L 2021 |
Title | NU9056, a KAT 5 inhibitor, treatment alleviates brain dysfunction by inhibiting NLRP3 inflammasome activation, affecting gut microbiota, and derived metabolites in LPS-treated mice |
Overall design | The aim of this study was to investigate whether NU9056 has a significant therapeutic effect on sepsis-associated encephalopathy in vivo and in vitro and the main possible reasons for these effects. Lipopolysaccharide (LPS) was used as the animal model of sepsis-associated encephalopathy. C57BL/6J mice were divided into the following 3 groups: (1) control group, (2) LPS group, and (3) LPS + NU9056 group. LPS-treated mice received an intraperitoneal injection of LPS (10 mg/kg), NU9056 (5 mg/kg) was intraperitoneally injected twice, 30 min before and 24 h after LPS injection. The concentration of fecal short-chain fatty acid consisting of acetate, propionic, isobutyric, butyric, isovalerate, and valerate were measured via gas chromatography-mass spectrometry (n = 5/group). |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Mouse; C57BL/6J mouse; |
Categories of depression | Animal model; Lipopolysaccharide induced depression model; Lipopolysaccharide induced depression model; |
Criteria for depression | Tail suspension test |
Sample size | 15 |
Tissue | Peripheral; Faece; Faece; |
Platform | MS-based; GC-MS: 5977 B apparatus (Agilent); |
PMID | |
DOI | |
Citation | Chen L, Qing W, Yi Z, et al. NU9056, a KAT 5 inhibitor, treatment alleviates brain dysfunction by inhibiting NLRP3 inflammasome activation, affecting gut microbiota, and derived metabolites in LPS-treated mice. Front Nutr. 2021 Jul 13;8:701760. |
Metabolite |
